Comparative Confusion: What Does FDA Intend For Opioid Comparative Efficacy Data?
Legally, FDA can't require comparative effectiveness data for approval, but draft guidance notes that the agency really wants it; for sponsors, that leaves more questions than answers, mainly: What will FDA do with an opioid application that doesn't contain such data.
You may also be interested in...
Although only a few companies commented on the FDA's draft guidance on the benefit/risk assessment of new opioids, they cut against conventional wisdom by supporting the agency's desire to see active comparator data.
US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.
US FDA also seeking feedback on whether the agency needs new authorities to better regulate opioid products.